How Moderna became the frontrunner for coronavirus vaccine
CNBC's Kelly Evans discusses Moderna and it's vaccine development plans with Greg Zuckerman, senior writer at the Wall Street Journal. For more coronavirus live updates: https://www.cnbc.com/2020/07/01/coronavirus-live-updates.html
Moderna’s stock fell by as much as 9.4% in midday trading Thursday after a report said the biotech company’s late-stage trial for a potential coronavirus vaccine will be delayed, possibly by a few weeks.
The company, which is working with the National Institutes of Health, was expected to begin a phase 3 trial with 30,000 participants for its vaccine candidate later this month, pending the results from its midstage trial.
However, the company is making changes to the trial plan, which has pushed back the expected start date, according to health-care publication STAT News, citing an investigator. STAT News said it’s unclear how long the start date will be delayed.
“My understanding was that they wanted to get the first vaccines given in July, and they say they’re still committed to do that,” one investigator told STAT News. “As best I can tell, they’re close to being on target for that.”
In response to the report, Moderna CEO Stephane Bancel told CNBC’s Meg Tirrell, “we have always said July. And I confirm July.”
The shares recovered some of the losses but still down by more than 5% in afternoon trading.
Moderna’s experimental vaccine contains genetic material called messenger RNA, or mRNA. The mRNA is a genetic code that tells cells what to build — in this case, an antigen that may induce an immune response to the virus. It became the first candidate to enter a phase 1 human trial in March.
Dr. Anthony Fauci, that nation’s leading infectious disease expert, has often touted the potential vaccine.
In May, the company released data from its early-stage trial, which showed the vaccine produced neutralizing antibodies against Covid-19 in at least eight participants. The vaccine also produced binding antibodies in all participants.
The effort by Moderna is one of several working on a potential vaccine for Covid-19, which has infected more than 10 million people and killed at least 516,970, according to data compiled by Johns Hopkins University. More than 100 vaccines are under development globally, according to the World Health Organization. At least 17 vaccines are already in clinical trials, according to the WHO.
On Wednesday, Pfizer released positive results from its closely watched early-stage human trial of a coronavirus vaccine.
The delay by Moderna could set back its goal of delivering data on whether its vaccine is safe and effective by the end of the year. If all goes well with Moderna’s next trial, the vaccine could be available for public distribution by the end of December or early 2021.
» Subscribe to CNBC TV: https://cnb.cx/SubscribeCNBCtelevision
» Subscribe to CNBC: https://cnb.cx/SubscribeCNBC
» Subscribe to CNBC Classic: https://cnb.cx/SubscribeCNBCclassic
Turn to CNBC TV for the latest stock market news and analysis. From market futures to live price updates CNBC is the leader in business news worldwide.
Connect with CNBC News Online
Get the latest news: http://www.cnbc.com/
Follow CNBC on LinkedIn: https://cnb.cx/LinkedInCNBC
Follow CNBC News on Facebook: https://cnb.cx/LikeCNBC
Follow CNBC News on Twitter: https://cnb.cx/FollowCNBC
Follow CNBC News on Instagram: https://cnb.cx/InstagramCNBC
#CNBC
#CNBCTV
Видео How Moderna became the frontrunner for coronavirus vaccine канала CNBC Television
Moderna’s stock fell by as much as 9.4% in midday trading Thursday after a report said the biotech company’s late-stage trial for a potential coronavirus vaccine will be delayed, possibly by a few weeks.
The company, which is working with the National Institutes of Health, was expected to begin a phase 3 trial with 30,000 participants for its vaccine candidate later this month, pending the results from its midstage trial.
However, the company is making changes to the trial plan, which has pushed back the expected start date, according to health-care publication STAT News, citing an investigator. STAT News said it’s unclear how long the start date will be delayed.
“My understanding was that they wanted to get the first vaccines given in July, and they say they’re still committed to do that,” one investigator told STAT News. “As best I can tell, they’re close to being on target for that.”
In response to the report, Moderna CEO Stephane Bancel told CNBC’s Meg Tirrell, “we have always said July. And I confirm July.”
The shares recovered some of the losses but still down by more than 5% in afternoon trading.
Moderna’s experimental vaccine contains genetic material called messenger RNA, or mRNA. The mRNA is a genetic code that tells cells what to build — in this case, an antigen that may induce an immune response to the virus. It became the first candidate to enter a phase 1 human trial in March.
Dr. Anthony Fauci, that nation’s leading infectious disease expert, has often touted the potential vaccine.
In May, the company released data from its early-stage trial, which showed the vaccine produced neutralizing antibodies against Covid-19 in at least eight participants. The vaccine also produced binding antibodies in all participants.
The effort by Moderna is one of several working on a potential vaccine for Covid-19, which has infected more than 10 million people and killed at least 516,970, according to data compiled by Johns Hopkins University. More than 100 vaccines are under development globally, according to the World Health Organization. At least 17 vaccines are already in clinical trials, according to the WHO.
On Wednesday, Pfizer released positive results from its closely watched early-stage human trial of a coronavirus vaccine.
The delay by Moderna could set back its goal of delivering data on whether its vaccine is safe and effective by the end of the year. If all goes well with Moderna’s next trial, the vaccine could be available for public distribution by the end of December or early 2021.
» Subscribe to CNBC TV: https://cnb.cx/SubscribeCNBCtelevision
» Subscribe to CNBC: https://cnb.cx/SubscribeCNBC
» Subscribe to CNBC Classic: https://cnb.cx/SubscribeCNBCclassic
Turn to CNBC TV for the latest stock market news and analysis. From market futures to live price updates CNBC is the leader in business news worldwide.
Connect with CNBC News Online
Get the latest news: http://www.cnbc.com/
Follow CNBC on LinkedIn: https://cnb.cx/LinkedInCNBC
Follow CNBC News on Facebook: https://cnb.cx/LikeCNBC
Follow CNBC News on Twitter: https://cnb.cx/FollowCNBC
Follow CNBC News on Instagram: https://cnb.cx/InstagramCNBC
#CNBC
#CNBCTV
Видео How Moderna became the frontrunner for coronavirus vaccine канала CNBC Television
Показать
Комментарии отсутствуют
Информация о видео
Другие видео канала
Citi's Drew Pettit on opportunities in nuclear energyFinal Trades: Leidos Holdings, Western Union and WalmartBreaking down shares of Hilton, Expedia and Match Group3-Stock Lunch: Ford, KB Home, & DoorDashCalls of the Day: Apollo Global, Cadence Design, Verizon, Expedia and NikeBond Report: 5-year auction well receivedBipartisan bill aims to let small businesses hedge commodity costs: Senators Shaheen and CassidyNielsen names NBCU top media distributor in AugustThree-Stock Lunch: S&P Homebuilders Index, Nvidia & JPMorganFinal Trades: Trane Tech, American Tower, Regeneron and Taiwan SemiTrade Tracker: Karen Firestone trims Adobe and buys more AutodeskEarnings trajectory is under-appreciated in the near-term, says HSBC's Max KettnerCalls of the Day: Starbucks, Uber, Lowe's, Walmart, Casey's General Store, AT&T and Charles SchwabMicron stock could continue to move higher, says BD8's Doran after Micron spikes on earningsTrade Tracker: Bill Baruch trims Tesla, sells SLB and buys more Exxon Mobil and Kinder MorganTrade Tracker: Steve Weiss sells Archer-DanielAsam: I'm not aware of any criminal investigations into SAP at present, We're cooperating with DOJFinal Trades: PayPal, Citizens Financial, Cisco Systems and the IYRYour Best Option: Micron earningsVistra overtakes Nvidia as S&P 500's top gainer in 2024Opening Bell, December 15, 2022